• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[胃肠道癌症的个性化治疗——可能性与局限性]

[Personalized therapy of gastrointestinal cancers--possibilities and limitations].

作者信息

Wichert G von, Adler G, Seufferlein T

机构信息

Innere Medizin I, Universität Ulm.

出版信息

Dtsch Med Wochenschr. 2010 Aug;135(34-35):1687-91. doi: 10.1055/s-0030-1262461. Epub 2010 Aug 18.

DOI:10.1055/s-0030-1262461
PMID:20721844
Abstract

The aim of palliative chemotherapy is to increase survival whilst maintaining optimal quality of life for the individual patient. While the best use of traditional chemotherapeutical agents continues to be explored, the introduction of targeted therapies has significantly broadened the therapeutic options. Yet it is interesting to note that the results of current trials did not always confirm the underlying molecular concepts. Recent data have suggested that altered pathways underlie the development of cancer, not just altered genes. Thus an effective therapeutic agent will have to target pathophysiologically relevant signalling networks, rather than individual proteins. This review presents current concepts and problems of cancer treatment, highlighting results from recent clinical trials of colorectal and pancreatic cancer patients and to discuss the current understanding of the underlying mechanisms.

摘要

姑息性化疗的目的是在维持个体患者最佳生活质量的同时延长生存期。在不断探索传统化疗药物最佳使用方法的同时,靶向治疗的引入显著拓宽了治疗选择。然而,值得注意的是,当前试验结果并非总能证实潜在的分子概念。最近的数据表明,癌症的发生不仅仅是基因改变,改变的信号通路才是其发病基础。因此,一种有效的治疗药物必须针对病理生理学相关的信号网络,而不是单个蛋白质。本综述介绍了癌症治疗的当前概念和问题,重点强调了近期结直肠癌和胰腺癌患者临床试验的结果,并讨论了对潜在机制的当前理解。

相似文献

1
[Personalized therapy of gastrointestinal cancers--possibilities and limitations].[胃肠道癌症的个性化治疗——可能性与局限性]
Dtsch Med Wochenschr. 2010 Aug;135(34-35):1687-91. doi: 10.1055/s-0030-1262461. Epub 2010 Aug 18.
2
[The RAS paradox of the EGFR-targeted therapy in colorectal cancer].[结直肠癌中表皮生长因子受体靶向治疗的RAS悖论]
Magy Onkol. 2008 Jun;52(2):185-91. doi: 10.1556/MOnkol.52.2008.2.7.
3
Targeting dynamics of subclones of GI, liver and pancreatic cancers.针对胃肠道、肝脏和胰腺癌亚克隆的动态变化。
Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):773-6. doi: 10.1080/17474124.2016.1179578. Epub 2016 May 3.
4
Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
J Clin Oncol. 2008 Mar 20;26(9):1400-1. doi: 10.1200/JCO.2007.14.7306.
5
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.西妥昔单抗联合伊立替康治疗难治性晚期结直肠癌患者的药物遗传学分析
J Clin Oncol. 2008 Mar 20;26(9):1427-34. doi: 10.1200/JCO.2007.12.4602.
6
Biomarkers for personalized medicine in GI cancers.用于胃肠道癌症个体化医学的生物标志物。
Mol Aspects Med. 2015 Nov;45:14-27. doi: 10.1016/j.mam.2015.06.002. Epub 2015 Jun 6.
7
[Progress of targeted therapy related to K-ras mutation].[与K-ras突变相关的靶向治疗进展]
Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):59-61.
8
Palliative chemotherapy in advanced gastrointestinal cancer.
Eur J Gastroenterol Hepatol. 2000 Apr;12(4):391-6. doi: 10.1097/00042737-200012040-00004.
9
Individualized therapy for metastatic colorectal cancer.转移性结直肠癌的个体化治疗。
J Intern Med. 2013 Jul;274(1):1-24. doi: 10.1111/joim.12070. Epub 2013 Apr 12.
10
[Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].[结直肠癌靶向治疗前KRAS的突变分析。瑞典分子病理学方法的质量控制]
Lakartidningen. 2010;107(5):255-9.